Related Experiment Video
Updated: Jul 10, 2026
10:22
Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
Molecular mechanisms underlying resistance to antimalarial compounds
1Division of Biological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.
Current Opinion in Microbiology
|July 8, 2026
Summary
Drug resistance in Plasmodium parasites threatens malaria control. Understanding these resistance mechanisms is key to developing new antimalarial drugs and monitoring parasite evolution.
Area of Science:
- Parasitology
- Molecular Biology
- Drug Discovery
Background:
- Antimalarial drug resistance in Plasmodium parasites is a significant obstacle to global malaria eradication efforts.
- The parasite employs diverse and evolving strategies to evade drug treatments, necessitating continuous research.
- Monitoring resistance is critical for effective public health interventions.
Purpose of the Study:
- To review the multifaceted mechanisms of Plasmodium drug resistance.
- To highlight recent advancements in understanding parasite resistance pathways.
- To discuss the development of next-generation antimalarial therapies.
Main Methods:
- Literature review of peer-reviewed scientific articles.
- Synthesis of data on Plasmodium resistance mechanisms.
- Analysis of current trends in antimalarial drug development.
Main Results:
- Plasmodium utilizes multiple genetic and biochemical pathways to develop resistance.
- Emerging resistance mechanisms pose new challenges to existing drug classes.
- Several novel antimalarial drug candidates are in various stages of development.
Conclusions:
- A comprehensive understanding of drug resistance is vital for malaria control.
- Identifying molecular markers aids in monitoring resistance in real-world settings.
- Continued innovation in antimalarial drug discovery is essential to overcome resistance.
More Related Videos
Related Concept Videos
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...